Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

Inclusion Criteria

• •Primary CNS lymphoma diagnosed histologically or by cerebrospinal fluid cytology; absence of systemic lymphoma manifestations
• •Relapse or lymphoma progression after/during high-dose methotrexate containing first-line chemotherapy or alternative therapy in the case of contraindications against high-dose methotrexate
• •ECOG performance score ≤ 2
• •Age ≥18 years and ≤ 75 years
• •Life expectancy of at least 3 months
• •Absence of active infection
• •Negative HIV serology
• •Adequate renal function (GFR \>30ml/h)
• •Adequate bone marrow reserve (neutrophils \> 1500/µl, platelets \> 80,000/µl)
• •Bilirubin \<1.5x upper limit of normal (ULN), ALT and AST \<3x ULN
• •At least 3 weeks interval from prior cytostatic treatment
• •Negative pregnancy test
• •Patient accessible for treatment and follow-up
• •Patient compliance
• •Signed informed consent